Myofibroblastic tumor of the esophagus - a case report of long-term follow-up and literature review

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

VACULOVÁ Jitka DOLINA Jiří JABANDŽIEV Petr ŠTĚRBA Martin TŮMA Jiří DOUŠEK Robert PLÁNKA Ladislav ŠENKYŘÍK Jan ŠTĚRBA Jaroslav BAJČIOVÁ Viera EID Michal PAVLOVSKÝ Zdeněk KALA Zdeněk KUNOVSKÝ Lumír

Year of publication 2021
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.linkos.cz/english-summary/klinicka-onkologie-journal/2021-08-15-4-en/myofibroblasticky-nador-jicnu-kazuistika-dlouhodoby-follow-up-a-prehled-literatu-1/
Doi http://dx.doi.org/10.48095/ccko2021313
Keywords inflamamtory pseudotumor; esophageal carcinoma; myofibroblastic tumor; plasma cell granuloma; endoscopy; surgery
Description Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm with intermediate malignant potential. Although most often seen in the lungs, it can occur at multiple anatomical locations, including the gastrointestinal tract. An esophageal lesion is extremely rare, however. IMTs present most commonly in children and young adults. The main therapeutic approach is surgical resection. Case report: We report on the follow-up of a case in a 13-year-old boy with IMT in the esophagus. He underwent surgical resection in 2013 and is free of disease to date. Conclusion: Surgical resection is the most preferred therapy. If the resection is complete, the risk of recurrence is low. Nevertheless, every patient should be carefully followed up after the resection.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.